Eli Lilly's Verzenio Significantly Improves Overall Survival in Early Breast Cancer Patients

Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy for the next 2 years. On August 27, Eli Lilly and Company announced that its drug, Verzenio (abemaciclib), combined with endocrine therapy/ET, significantly improved overall survival/OS in patients with hormone receptor-positive/HR+, HER2-negative, high-risk early breast cancer.

The results came from the primary OS analysis of the Phase 3 monarchE trial, which enrolled 5,637 adults across 38 countries. The study specifically focused on a high-risk population. The trial found that a 2-year course of Verzenio plus ET provided a statistically significant and clinically meaningful improvement in OS compared to ET alone.

A 7-year landmark analysis also showed sustained benefits in invasive disease-free survival/IDFS and distant relapse-free survival/DRFS, reinforcing the drug’s effectiveness. The safety profile of Verzenio remained consistent with previous reports, with all patients having completed or discontinued the two-year treatment regimen.

Eli Lilly and Company (NYSE:LLY) discovers, develops, and markets human pharmaceuticals in the US, Europe, China, Japan, and internationally.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.